-
2024-511651-17-00
4
2021-09-21
Myelodysplastic syndrome
-
2023-507728-22-00
3
2021-06-25
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
-
2023-505483-11-00
6
2021-05-02
Brain abscess
-
2022-501874-21-00
6
2020-12-15
Takotsubo syndrome
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-510527-29-00
4
2020-09-01
Cancer
-
2024-512186-14-00
6
2020-08-24
Fluid overload/fluid accumulation
-
2023-507885-21-00
4
2020-08-18
Chronic Inflammatory Demyelinating Polyneuropathy
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2023-506546-23-00
5
2020-05-20
Acute myeloid leukemia
-
2023-509847-29-00
7
2020-04-09
Advanced solid tumors
-
2023-504653-12-00
4
2020-02-10
Patients with previously untreated Richter Transformation or patients
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2024-512606-25-00
7
2019-12-20
Advanced Solid Tumors
-
2024-517387-37-00
4
2019-12-12
Small abdominal aortic aneurysm (AAA) under active surveillance; 30-49
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-513766-20-00
9
2019-12-03
Hematological malignancies
-
2023-506131-15-00
5
2019-09-10
Juvenile Idiopathic Arthritis
-
2024-517854-91-00
5
2019-08-05
Metastatic or high-risk recurrent prostate cancer managed with androge
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-515690-10-00
9
2019-05-10
Follicular B-cell non-Hodgkin's lymphoma
-
2024-518057-41-00
6
2019-02-22
Unexplained cardiac arrest patients after thorough investigations (Idi
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia